$CWCO

Consolidated Water Q2FY26 Results: Net profit falls 23% to $4.0 million

Consolidated Water (CWCO) reported a 23% decline in Q2 2026 net income to $4.0M, with revenue down 2% to $32.9M. The drop was driven by a 49% fall in manufacturing revenue, partially offset by growth in bulk and retail segments. The company secured a 25-year water utility license in Grand Cayman and received significant new orders in Florida, signaling future growth.

Original reporting
Published Aug 25, 2026, 9:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Consolidated Water Q2FY26 Results: Net profit falls 23% to $4.0 million — source image
Decision brief

The 30-second read

$CWCOBearishMed
01

Why it matters

The earnings miss may trigger short‑term price pressure, yet the new contract pipeline could support a longer‑term upside narrative.

02

Market read

Earnings release for a small‑cap utility with modest financial impact but notable contract wins.

03

What to watch

Cash position of $132.6M provides flexibility for acquisitions; low debt reduces financial risk.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Consolidated Water Co Ltd (NASDAQ: CWCO) released its Q2 2026 earnings, showing a 23% profit decline but announcing a 25‑year license in Grand Cayman and sizable Florida orders.

Company-level read

Ticker impact

$CWCOBearishMedium confidence
Context

Q2 2026 net income fell 23% to $4.0M and revenue slipped 2% to $32.9M, with a new 25‑year water license in Grand Cayman.

Expected impact

Potential short‑term downside pressure, but price could stabilize if investors value the new contract pipeline.

Evidence & confidence

Profit decline is material for a small‑cap, but the magnitude ($4M) is modest; the contract news adds a positive catalyst but may be priced in gradually.

Market effects

Highlights weakness in water‑utility manufacturing while underscoring growth potential in desalination and municipal contracts.

Positive signal for Caribbean water‑service markets; modest relevance for U.S. municipal water equipment suppliers.

Limited; primarily affects niche water‑utility sector.

Counterpoint

The earnings miss may be overstated; the long‑term license and Florida orders could drive earnings rebound faster than the market expects.

Key entities

  • Consolidated Water Co Ltd

    U.S.-listed water utility and services provider.

Related articles

$CWCOMed

Consolidated Water (CWCO) Q2 2026 Earnings Call Transcript

Consolidated Water (CWCO) reported Q2 2026 revenue of $32.9M, down 2% YoY, driven by a 49% drop in manufacturing revenue. Net income from continuing operations was $4.0M, or $0.25 diluted EPS, vs $5.2M, or $0.32. Cash was $132.6M at June 30, 2026. The company cited permitting delays in Hawaii and growth in bulk and services.

$CWCOMed

Consolidated Water Q2 Earnings Call Highlights

Consolidated Water (NASDAQ:CWCO) reported Q2 services revenue up 1% to $11.6M, helped by construction work in Colorado and California, partly offset by lower O&M after two customer contracts expired. Manufacturing revenue fell 49% to $2.7M. Gross profit was $11.0M (33% of revenue). The company received a 25-year Grand Cayman license, and noted Hawaii desalination and Florida equipment orders.

$CWCOMed

Consolidated Water Reports Second Quarter 2026 Results

Consolidated Water Co. Ltd. (CWCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Consolidated Water Reports Second Quarter 2026 Results ​ GEORGE TOWN, Grand Cayman, Cayman Islands, August 10, 2026 -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, re

$GEHCHighAI 9/10

GE HealthCare Q3 2026 slides: margin gains fuel guidance raise

GE HealthCare (GEHC) reported Q3 2026 revenue of $5.5B, up 6.2%, and EPS of $1.34, up 25.1%. The company raised full-year guidance due to margin expansion and operational improvements. Shares rose 6.9% to $76.02. All segments showed growth, with Pharmaceutical Diagnostics leading at 13.8%. Free cash flow increased to $793M. Guidance updated for higher revenue, EPS, and free cash flow.